According global population aging there is an increase in the absolute and relative numbers of people in older age groups. Therefore, senile asthenia (SA) is very relevant. An association between SA and cardiovascular disease has been proven. In addition, there is an increase of aging anemia. At the same time, mortality in patients with anemia, including anemia, which is caused by cardiovascular diseases, increases. Purpose of the study: To study the association of anemia with cardiovascular pathology in patients who have SA syndrome. 168 over 65-year-old patients were examined. The main group contains 60 patients with SA syndrome (37 men, 23 women); control group includes 108 people (68 men, 40 women) without SA syndrome. The median age of patients in the main group did not statistically significantly differ from the median age of people in the control group (82 years ±7.4 [75.00; 84.00] years versus 78 years ±7.1 [65.00; 82.00] years, p=0.605). All patients had a comprehensive geriatric assessment (CGE). Statistically, anemia in patients with SA is diagnosed more frequently in comparison with patients without SA (51.67% vs. 33.33%, p<0.001). Statistically, significant negative correlations were determined among the hemoglobin level and senile asthenia (r=-0.222; p<0.001), hematocrit and senile asthenia (r=-0.224; p<0.001). There are statistically significant direct correlations between anemia in patients with SA with frequent supraventricular extrasystole (r=0.152; p=0.049) and frequent ventricular extrasystole (r=0.154, p=0.047). Conclusion: The association of SA with anemia was confirmed, whereas anemia in patients, who have SA syndrome, affects the occurrence of frequent supraventricular and frequent ventricular extrasystoles.
Aim. To conduct a pharmacoepidemiological study to determine the characteristics of antihypertensive therapy in older patients with senile asthenia syndrome (SSA) and compliance of this therapy with modern clinical recommendations. Materials and methods. The study included 146 patients diagnosed with stage IIII hypertension who underwent inpatient treatment in the therapeutic department of the Krasnoyarsk Regional Hospital for War Veterans, the subjects were divided into two groups. The first group included 55 elderly patients (WHO, 2012) with hypertension and SSA. The second group included 35 elderly patients (WHO, 2012) with hypertension and SSA. The comparison group consisted of 56 patients aged 60 to 84 years with hypertension without SSA. Evaluation of the pharmacotherapy was carried out based on extracts from the medical histories of inpatient patients. Results. The most commonly taken groups of antihypertensive drugs in patients of older age groups with hypertension and SSA according to the study are diuretics and -blockers. Diuretics were taken by 88.6% of elderly patients and 83.6% of senile patients. The main combinations of antihypertensive drugs in patients with hypertension and SSA were: a two-component scheme of combination of an ACE inhibitor and a diuretic, a three-component scheme of combination of an ACE inhibitor, a -blocker and a diuretic, four-component schemes of combination of an ACE inhibitor, a -blocker, a calcium channel blocker and a diuretic, as well as a combination of an angiotensin II receptor blocker, a -blocker, calcium channel blocker and diuretic with combined medications. Conclusion. The prescribed antihypertensive therapy in patients of older age groups with hypertension and SSA in most cases is represented by a combination of several drugs. Many patients take three-component antihypertensive therapy regimens. There were no statistically significant differences between patients of older age groups with hypertension and SSA, as well as patients of older age groups with hypertension without SSA. Therefore, it can be concluded that the presence of senile asthenia syndrome does not affect the tactics of treatment of hypertension and regardless of the presence or presence of SSA, patients receive the same hypotensive therapy, which contradicts existing clinical guidelines.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.